Paper Details

  1. Home
  2. Paper Details

Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease.

Author: GrossbergGeorge T, MengXiangyi, OlinJason, SchmittFrederick A, TekinSibel

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Rivastigmine patch, a medication for Alzheimer's disease (AD), showed improvements in memory, language, and praxis compared to placebo in patients with mild-to-moderate AD.
Paper Details　
Original Abstract of the Article :
Alzheimer's disease (AD) patients treated with rivastigmine transdermal patch have shown statistically significant differences versus placebo on the AD Assessment scale-cognitive subscale (ADAS-cog). In this retrospective analysis of a double-blind, placebo- and active-controlled, 24-week clinical t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/1533317510385808

データ提供：米国国立医学図書館（NLM）

Rivastigmine Patch: A Oasis for Cognitive Function in Alzheimer's Disease

Alzheimer's disease (AD) is a challenging neurological condition that affects cognitive function, particularly memory, language, and praxis. This research investigates the effects of transdermal rivastigmine on cognitive function in patients with mild-to-moderate AD. The authors analyze data from a clinical trial to evaluate the impact of rivastigmine on specific cognitive domains and individual items of the AD Assessment Scale-Cognitive Subscale (ADAS-cog). Their findings provide valuable insights into the potential benefits of rivastigmine in improving cognitive function in patients with AD.

Rivastigmine: A Beacon of Hope in the Desert of Cognitive Decline

This study provides a glimmer of hope in the desert of cognitive decline associated with Alzheimer's disease. The authors demonstrate that rivastigmine patch can offer significant improvements in memory, language, and praxis domains, suggesting its potential as a valuable treatment option for patients with AD.

Navigating the Desert of Alzheimer's: A Multifaceted Approach

This research reminds us that the desert of Alzheimer's disease can be navigated more effectively with a multifaceted approach. Understanding the potential benefits of medications like rivastigmine, alongside other supportive therapies, can help improve the quality of life for individuals living with this challenging condition.

Dr.Camel's Conclusion

This study offers valuable insights into the potential benefits of rivastigmine patch for improving cognitive function in patients with Alzheimer's disease. The findings suggest that rivastigmine may offer a beacon of hope in the desert of cognitive decline, providing a valuable tool to help individuals with AD maintain their quality of life.

Date :
  1. Date Completed 2011-06-07
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

21131668

DOI: Digital Object Identifier

10.1177/1533317510385808

Related Literature

Article Analysis
・Effects of rivastigmine transdermal patch
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.